Postoperative pain control remains a major challenge for patients, providers, and healthcare systems with no tools available to routinely personalize medication selection. Multiple genes have been implicated in explaining some of the variation among postoperative patient response, and initial randomized controlled trials indicate that single‑gene pharmacogenetic analysis can improve postop outcomes. However, most professional guidelines to date (e.g., CPIC) only provide recommendations for single gene/drug interactions.
In this webinar, Jeremy Stuart, CSO of Precision Genetics, will discuss the PRospective Outcomes and Molecular Implementation Support Registry (PROMISRx) study that aims to better explain the interpatient variability in response to perioperative medications/treatments in an effort to predict postoperative outcomes. Stuart will share data on key genetic analysis assays, including variable‑number tandem repeat (VNTR) detection of serotonin transporter genes and various opioid receptor sites using fragment analysis.
You will learn about:
- Avenues for improved pharmacogenetic analysis
- Multivariant analysis using fragment analysis
- Benefits of cooperative relationships between service providers and health systems
Speaker
Jeremy Stuart
Chief Scientific Officer
Precision Genetics
Jeremy Stuart has extensive management experience in the life science industries. He specializes in commercial operations, technology development and transfer, manufacturing design, start‑up and analytical validation of laboratory‑developed tests. Stuart was part of the senior management team of Selah Genomics and was involved in its sale to EKF. Previously, he was a key member of the Agencourt Personal Genomics team. Stuart led the development, and validation of all of Selah's molecular assays and led the commercialization and application efforts for next‑generation sequencing at Life Technologies. While at Agencourt Personal Genomics, Stuart co‑developed the SOLiD next‑generation sequencing technology and he co‑authored several patents related to next‑generation sequencing. Before entering industry, Stuart completed his postdoctoral work at the department of genetics and complex diseases at the Harvard School of Public Health. Stuart earned his master's degree in toxicology from the University of Minnesota and his doctorate from Harvard University.
Please fill out the form below to access this webinar.